Explore the Agenda

7:30 am Check-In & Morning Coffee

8:20 am Chair’s Opening Remarks

Co-founder, President and CEO, Interdict Bio

Navigating the Evolving TPD Landscape to Understand Future Directions & Drive the Next-Generation of Proximity Therapeutics

8:30 am Panel Discussion: The TPD Investment Landscape: Lessons from Deals in 2025 & Expectations for 2026

Executive Director & Vice President - Business Development, Emerging Sciences & Innovation, Partner, Pfizer
Co-founder, President and CEO, Interdict Bio
Chief Business Officer, Foghorn Therapeutics
Senior Director, Head of Business Development & Strategic Finance, Degron Therapeutics
Principal, Perceptive Advisors LLC
Business Development Project Leader, Pharma Partnering, Genentech
Chief Executive Officer, PhoreMost

9:15 am Discovery of a VHL-Based Molecular Glue Degrader Targeting GEMIN3 Using Picowell RNA-Sequencing

Executive Director & Head of Induced Proximity Platform, Amgen Inc.

9:45 am Illuminating New Insights in Targeted Protein Degradation Kinetics, Mechanisms, & Selectivity

R&D Group Leader, Promega Corporation

10:15 am Expanding Targeted Glue Applications by Recruiting Novel E3 Ligases Across Diverse Targets

Chief Scientific Officer, Amphista Therapeutics

10:45 am Morning Break & Networking

Track A: Discovery

Utilizing Novel Discovery Platforms to Find Potent & Selective Molecular Glues to Progress Cures Against Autoimmune & Cancer Indication

11:30 am Orally Bioavailable NRF2 Molecular Glue Degrader Effective in KEAP1-Mutant Cancer

Chief Executive Officer, Arpeggio Bio
  • Novel HTS Transcriptomics screen identifies initial NRF2 hit
  • Hit and Analog induces an interaction between NRF2 and BTrCP
  • Optimized analogs lead to significant in vivo activity in multiple lung cancer models with very favorable drug-like and safety profiles

Download the Full Event Guide for Full Session Details.

12:00 pm Targeting Mutant KRAS Oncoproteins with Molecular Glues: A TUBE-Based Screen Identifies a Novel Degradation Pathway

Vice President, Research and Development, Lifesensors
  • Tandem Ubiquitin Binding Entity (TUBE) platform to discover novel molecular glues targeting mutant KRAS
  • KRAS Mol Glue, coopting a novel E3 ligase to ubiquitinate and degrade mutant KRAS
  • Pan KRAS degrader downregulates MAPK signaling
  • Chain selective poly-ubiquitin TUBEs, K48 or K63, elucidate MOA of the compounds
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development

12:30 pm Lunch Break & Networking

Track A: Discovery

Designing Innovative Activating Molecular Glues Through Structure-Guided Design & AI/ML to Unlock New Therapeutic Opportunities

1:30 pm Structure-Based Development of Non-Degrader Molecular Glues to Selectively Stabilize a Tumor Suppressor Phosphatase Complex

Head of Structural Biology (Rappta Therapeutics); Professor (Case Western Reserve University), Rappta Therapeutics
  • A tool compound (DT-061) selectively stabilizes B56α-containing PP2A heterotrimers, enhancing their pro-apoptotic functions and driving dephosphorylation of its oncogenic substrate, c-Myc
  • Cryo-EM structure of DT-061 bound to its binding pocket identifies a trimeric interface of PP2A subunits, defining the molecular basis for its selective stabilization and therapeutic potential
  • Structure-based drug design was used to develop new chemical compounds that also behave like molecular glues, but with improved pharmacokinetic properties

Download the Full Event Guide for Full Session Details.

2:00 pm Panel Discussion: Cracking the Code: Understanding & Measuring Cooperativity in Induced Proximity Modalities

Vice President & Head of Chemistry, Rapafusyn Pharmaceuticals
Director - Biophysics, High Throughput Screening & Oncology, Pfizer
Exe, Revolution Medicines

2:30 pm Building A Computational Design Platform For Any Molecular Glue

Chief Executive Officer, Ternary Therapeutics
  • Discussing the requirements of a successful molecular glue design platform
  • Blending the speed and scalability of Machine Learning with the accuracy of Physics-Based Methods for optimal protein-protein matching and ternary complex structure prediction
  • Computational design and experimental validation of optimised molecular glue degraders and activators

Track B: Pre-Clinical Development
Track C: Translational & Clinical Development

3:00 pm Afternoon Break & Networking

3:30 pm Harnessing Degradation to Achieve Selectivity & First-in-Class Targeting of Challenging Chromatin Regulatory Proteins

Chief Scientific Officer, Foghorn Therapeutics

Securing the Future of Induced Proximity with Pioneering Academic Breakthroughs & Emerging Biotech Pioneers Ready to Take 2026 by Storm

4:00 pm Degrader Antibody Conjugates (DACs): Targeted Protein Degraders (TPD) as Next-Generation Antibody Drug Conjugate (ADC) Payloads

Senior Vice President & Head of Early Drug Discovery, Nurix Therapeutics
  • By combining the ability of a TPD to selectively remove a protein of interest with the cell specificity of antibodies, DACs have the potential for greater efficacy and broader therapeutic application than traditional cytotoxic ADC payloads
  • Improved safety can be achieved through the layers of specificity provided by degrader selectivity, ligase expression, and antibody targeting
  • DACs are more than the sum of their parts and are best optimized combinatorially
  • Antibody delivery can expand the applicability of novel ligase ligands in TPD beyond those commonly used for oral small molecules

4:30 pm tPRIME: A Novel Induced Proximity Approach to Targeting p53-Y220C Mutant Cancers

Vice President - Biology, Photys Therapeutics

5:00 pm Chair’s Closing Remarks & End of Industry Day 2